Dr Reddys Laboratories (RDY) Accounts Payables (2009 - 2026)

Dr Reddys Laboratories has reported Accounts Payables for 18 years, with the latest figure at $396.1 million in Q2 2026.

• On a quarterly basis, Accounts Payables fell 9.51% year-over-year to $396.1 million in Q2 2026; TTM through Jun 2026 was $396.1 million, a 9.51% decrease from a year earlier, with the FY2026 full-year figure at $356.0 million, down 14.63% from the prior year.
• Accounts Payables was $396.1 million for Q2 2026 at Dr Reddys Laboratories, up from $365.5 million in the prior quarter.
• The five-year high for Accounts Payables was $461.4 million in Q3 2025, with the low at $285.7 million in Q3 2022.
• Average Accounts Payables over 5 years is $379.6 million, with a median of $373.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables decreased 17.15% in 2022, then advanced 29.08% in 2023.
• Over 5 years, Accounts Payables stood at $317.0 million in 2022, then increased by 17.89% to $373.7 million in 2023, then advanced by 14.18% to $426.6 million in 2024, then gained by 7.38% to $458.1 million in 2025, then dropped by 13.54% to $396.1 million in 2026.
• The last three Accounts Payables figures came in at $396.1 million (Q2 2026), $365.5 million (Q1 2026), and $458.1 million (Q4 2025), per Business Quant data.